Company: INTS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001567264-25-000039
Chunk: 51

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 51
---
 service organization for services performed, which is recognized in research and development expenses on the statement of operations.  As of March 31, 2025, the Company recognized $1,800 in accrued expenses.

11

Note 12. Segments

The Company has a single segment and allocates resources based on cash resources and operating expense projections. The table below summarizes the significant expense categories regularly reviewed by the Company’s president and chief executive officer, who is the Company’s chief operating decision maker (“CODM”), for the three months ended March 31, 2025 and 2024:Three Months Ended March 31,20252024Research and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $53 INVINCIBLE-2 Study (Phase 2 Breast)— 103 INVINCIBLE-3 Study (Phase 3 Sarcoma)1,596 1,419 INVINCIBLE-4 Study (Phase 2 Breast)63 — Clinical trial expenses1,659 1,575 Contract manufacturing24 214 Salaries and benefits related329 394 Consulting & Other(a)17 66 Stock-based compensation160 566 Research and development expenses2,189 2,815 General and administrative expenses:Salaries and benefits related230 324 Legal fees167 257 Audit fees77 115 Consulting196 173 Insurance157 286 Other(b)103 184 Stock-based compensation275 589 General and administrative expenses1,205 1,928 Loss from operations(3,394)(4,743)Other segment items(c)47 140 Net loss$(3,347)$(4,603)(a)Consulting & Other includes research and development consulting costs and travel-related costs. (b)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs. 

(c)Other segment items include interest income, interest expense, and foreign exchange gains and losses. 

Note 13.    Subsequent Events

Public offeringOn April 24, 2025, the Company commenced a best efforts public offering (the “Offering”) of an aggregate of (i) 3,133,333 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), (ii) 3,133,